Transition Therapeutics makes licensing pact for Lilly arthritis drug

Toronto-based Transition Therapeutics ($TTHI) today announced that it has acquired exclusive licensing of worldwide rights for Eli Lilly's ($LLY) experimental drug TT-601 for arthritis pain, Reuters reports. The drug has completed preclinical development, and Transition said it hopes to start human trials in the first half of 2014. Under the agreement, Lilly retains an option to reacquire all rights to TT-601 following review of clinical proof-of-concept study results. If Lilly exercises this option right, Transition could receive milestone payments of about $130 million and another royalty payment on sales of any products containing TT-601. The news caused shares of Transition to soar 22% on Tuesday. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.